{
  "ticker": "RCUS",
  "company_name": "Arcus Biosciences, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03628677",
      "title": "A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Unspecified, Adult",
      "start_date": "2018-09-12",
      "completion_date": "2025-01-23",
      "enrollment": 0,
      "sponsor": "Arcus Biosciences, Inc."
    },
    {
      "nct_id": "NCT03629756",
      "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer",
      "start_date": "2018-07-24",
      "completion_date": "2021-09-03",
      "enrollment": 0,
      "sponsor": "Arcus Biosciences, Inc."
    },
    {
      "nct_id": "NCT04656535",
      "title": "AB154 Combined With AB122 for Recurrent Glioblastoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "EARLY_PHASE1",
      "condition": "Glioblastoma",
      "start_date": "2021-04-21",
      "completion_date": "2026-12-31",
      "enrollment": 0,
      "sponsor": "Yale University"
    },
    {
      "nct_id": "NCT04736173",
      "title": "Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer",
      "start_date": "2021-02-08",
      "completion_date": "2027-05",
      "enrollment": 0,
      "sponsor": "Arcus Biosciences, Inc."
    },
    {
      "nct_id": "NCT05130177",
      "title": "Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Melanoma",
      "start_date": "2022-03-16",
      "completion_date": "2031-01",
      "enrollment": 0,
      "sponsor": "Diwakar Davar"
    },
    {
      "nct_id": "NCT05411146",
      "title": "A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Participants",
      "start_date": "2022-05-25",
      "completion_date": "2022-07-07",
      "enrollment": 0,
      "sponsor": "Arcus Biosciences, Inc."
    },
    {
      "nct_id": "NCT06727565",
      "title": "Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Head and Neck Squamous Cell Carcinoma",
      "start_date": "2025-02-18",
      "completion_date": "2026-08",
      "enrollment": 0,
      "sponsor": "Gilead Sciences"
    },
    {
      "nct_id": "NCT04892875",
      "title": "A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Larynx Cancer, Pharynx Cancer, Hypopharynx Cancer, Hypopharynx Squamous Cell Carcinoma",
      "start_date": "2023-12-31",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Jennifer Choe"
    },
    {
      "nct_id": "NCT03719326",
      "title": "A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "TNBC - Triple-Negative Breast Cancer, Ovarian Cancer",
      "start_date": "2018-10-15",
      "completion_date": "2021-07-02",
      "enrollment": 0,
      "sponsor": "Arcus Biosciences, Inc."
    },
    {
      "nct_id": "NCT05329766",
      "title": "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Gastrointestinal Tract Malignancies",
      "start_date": "2022-06-10",
      "completion_date": "2027-06",
      "enrollment": 0,
      "sponsor": "Arcus Biosciences, Inc."
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1": 23,
      "EARLY_PHASE1": 1,
      "PHASE2": 16,
      "PHASE3": 6,
      "PHASE1, PHASE2": 4
    },
    "by_status": {
      "COMPLETED": 19,
      "ACTIVE_NOT_RECRUITING": 12,
      "RECRUITING": 13,
      "WITHDRAWN": 2,
      "SUSPENDED": 1,
      "NOT_YET_RECRUITING": 1,
      "TERMINATED": 2
    },
    "active_trials": 25,
    "completed_trials": 19,
    "conditions": [
      "Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction",
      "Advanced Cancer",
      "Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)",
      "Advanced Clear Cell Renal Cell Carcinoma",
      "Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors",
      "Advanced Non-Small Cell Lung Cancer",
      "Advanced Pancreatic Cancer",
      "Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer",
      "Advanced Solid Tumors",
      "Advanced Upper Gastrointestinal Tract Adenocarcinoma",
      "Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer",
      "Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma",
      "Cancer",
      "Clear Cell Renal Cell Carcinoma, Solid Tumors",
      "GastroEsophageal Cancer, Colorectal Cancer",
      "Gastrointestinal Tract Malignancies",
      "Glioblastoma",
      "Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Larynx Cancer, Pharynx Cancer, Hypopharynx Cancer, Hypopharynx Squamous Cell Carcinoma",
      "Head and Neck Squamous Cell Carcinoma",
      "Healthy Participants",
      "Healthy Volunteers",
      "Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma",
      "Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer",
      "Melanoma",
      "Metastatic Castration-resistant Prostate Cancer, Prostate Cancer",
      "Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma",
      "Metastatic Colorectal Cancer",
      "Metastatic Pancreatic Ductal Adenocarcinoma",
      "Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation",
      "Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer",
      "Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer",
      "Non-Small Cell Lung Cancer",
      "Non-small Cell Lung Cancer",
      "Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer",
      "Oligometastatic Prostate Cancer",
      "Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas, Adenosquamous Carcinoma of the Pancreas",
      "Pancreatic Ductal Adenocarcinoma",
      "Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer",
      "Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant",
      "Rectal Cancer",
      "Solid Tumor, Unspecified, Adult",
      "TNBC - Triple-Negative Breast Cancer, Ovarian Cancer"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:24.064109",
    "search_query": "Arcus Biosciences, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Arcus+Biosciences,+Inc."
  }
}